TLRY

Tilray Brands, Inc.

Fundamental data last updated:September 21, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

Pending Announcement

Business Summary

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

 


VALUATION

P/E

-0.34

Market Cap ($M USD)

$675.76M

Forward P/E

6.81

PEG

0.06

PRICE TO SALES

0.57

PRICE TO BOOK

0.41

EV / EBITDA

-0.43

5-Year Average P/E

Free Cash Flow Yield

-14.16%

DCF Value

$-48.76

Graham Number

N/A

Price to FCF

-7.06

EV to FCF

-8.24

Earnings Yield

-289.97%

FCF Yield

-14.16%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$16.38

Next Year EPS Growth Estimate

$0.83

Next Year Revenue Growth Estimate

$1.30B

Return on Equity (ROE)

-92.82%

FREE CASH FLOW

Operating Margin

-172.33%

Debt-to-Equity

0.22

Piotroski F-Score

4

Altman Z-Score

-4.57

Return on Invested Capital (ROIC)

-112.09%

Current Ratio

2.79

Quick Ratio

1.66

Net Debt to EBITDA

-0.06

Interest Coverage

-70.42

Gross Profit margin

27.67%

FCF PER SHARE

$-0.85

REVENUE PER SHARE

$10.49

Gainseekers Quantitative Analysis

Summary

The market’s current valuation of TLRY seems to be a stark mispricing when juxtaposed with its DCF Value, which is deeply negative. The Forward P/E of 6.70 suggests optimism for future earnings, yet the Altman Z-score of -4.60 signals distress. Earnings Yield is alarmingly negative, indicating poor profitability. With a Price/Book ratio of 0.40, the market is pricing TLRY below its book value, reflecting skepticism about its asset utilization and future growth prospects. This paints a picture of a company struggling to justify its existence in the eyes of investors.

AI Exposure / Tech Reliance

Operating in the healthcare sector, specifically within drug manufacturing, TLRY is positioned to leverage AI for drug discovery and personalized medicine. However, the industry's slow adaptation to tech shifts may hinder rapid integration. The company's ability to harness AI could be pivotal in maintaining competitiveness.

The Bull Case

For the value-driven investor, TLRY's Forward PEG ratio of 0.06 is a beacon of potential undervaluation, suggesting growth at a bargain. Despite a negative ROIC, the company's low Debt/Equity ratio of 0.22 indicates financial prudence. The Piotroski F-Score of 4 hints at moderate financial health, while a Current Ratio of 2.79 suggests liquidity strength. These metrics could appeal to those betting on a turnaround story.

The Bear Case

TLRY's structural weaknesses are glaring, with a Return on Equity of -92.82% and an Operating Margin of -172.33%, indicating severe inefficiencies. The negative EV to EBITDA ratio underscores a lack of operational profitability. Furthermore, the stock's distance from its 52-week high by 317.27% suggests significant investor disillusionment. These factors, combined with a negative FCF Yield, paint a grim picture of financial instability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$10.00

Institutional Ownership %

1-Year Beta

1.94

Insider Buying % (6 Mo)

Distance to 52-Week High

310.62%

Distance to 52-Week Low

38.05%

EARNINGS SURPRISE %

-71.43%

50-DAY SMA

$6.23

200-DAY SMA

$9.67

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.